Literature DB >> 3219280

Breast cancer and the pill--a further report from the Royal College of General Practitioners' oral contraception study.

C R Kay1, P C Hannaford.   

Abstract

An analysis of the occurrence of breast cancer in this long-term prospective cohort study shows a significant relative risk (RR) in women who have ever used oral contraceptives (OC) of 3.33 in women age 30 to 34 years at diagnosis and an RR of 5.88 (P = 0.0011) in women who were parity 1 at the time of diagnosis. In women below the age of 35 years the RR of 2.38 was not significant. There was no increased risk in women over the age of 35 years. A significant trend relating to duration of use was demonstrable in women who were parity 1 in the analysis of both current and ever-users. An analysis by time since stopping OC use revealed a significant trend in all ever-users, but the trends were much steeper in women of parity 1 or aged 30 to 34 years at diagnosis. There was no evidence that the increased rates in OC users were related to the oestrogen or progestogen dose. The 5 year survival rate in users diagnosed under the age of 35 years was significantly poorer than in comparable non-users. It is possible that the increased rates in younger OC users might be due to an accelerated presentation of breast cancer in those women who would otherwise have been diagnosed at a later time. The non-significant excess risk in users under 35 years of age was approximately 1 in 7,000 users per year. The unresolved discrepancies between the results of the published studies make it impossible at the present time to decide whether or not OC use is associated with an increased risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219280      PMCID: PMC2246833          DOI: 10.1038/bjc.1988.285

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Estimability and estimation in case-referent studies.

Authors:  O Miettinen
Journal:  Am J Epidemiol       Date:  1976-02       Impact factor: 4.897

2.  Oral contraceptives and breast cancer: a national study.

Authors:  C Paul; D C Skegg; G F Spears; J M Kaldor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-20

3.  Oral contraceptive use and breast cancer in young women in Sweden.

Authors:  H Olsson; M L Olsson; T R Möller; J Ranstam; P Holm
Journal:  Lancet       Date:  1985-03-30       Impact factor: 79.321

4.  Breast cancer risk in relation to early oral contraceptive use.

Authors:  D R Miller; L Rosenberg; D W Kaufman; D Schottenfeld; P D Stolley; S Shapiro
Journal:  Obstet Gynecol       Date:  1986-12       Impact factor: 7.661

5.  Age at first birth and breast cancer risk.

Authors:  B MacMahon; P Cole; T M Lin; C R Lowe; A P Mirra; B Ravnihar; E J Salber; V G Valaoras; S Yuasa
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

6.  Breast cancer and oral contraceptive use.

Authors:  L Rosenberg; D R Miller; D W Kaufman; S P Helmrich; P D Stolley; D Schottenfeld; S Shapiro
Journal:  Am J Epidemiol       Date:  1984-02       Impact factor: 4.897

7.  Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.

Authors:  M C Pike; B E Henderson; M D Krailo; A Duke; S Roy
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

8.  Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway.

Authors:  O Meirik; E Lund; H O Adami; R Bergström; T Christoffersen; P Bergsjö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

9.  Early oral contraceptive use and breast cancer: results of another case-control study.

Authors:  K McPherson; M P Vessey; A Neil; R Doll; L Jones; M Roberts
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

10.  Oral contraceptive use and early abortion as risk factors for breast cancer in young women.

Authors:  M C Pike; B E Henderson; J T Casagrande; I Rosario; G E Gray
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

View more
  23 in total

Review 1.  Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill?

Authors:  H Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

2.  Recent oral contraceptive use and risk of breast cancer (United States)

Authors:  P A Newcomb; M P Longnecker; B E Storer; R Mittendorf; J Baron; R W Clapp; A Trentham-Dietz; W C Willett
Journal:  Cancer Causes Control       Date:  1996-09       Impact factor: 2.506

3.  The contraceptive pill and breast cancer in young women.

Authors:  P C Hannaford; C R Kay
Journal:  BMJ       Date:  1989-06-10

4.  Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study.

Authors:  A G Schuurman; P A van den Brandt; R A Goldbohm
Journal:  Cancer Causes Control       Date:  1995-09       Impact factor: 2.506

Review 5.  Oral contraceptives and cancer. A review of the evidence.

Authors:  C La Vecchia; A Tavani; S Franceschi; F Parazzini
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

Review 6.  Estrogen replacement therapy in women at increased risk for breast cancer.

Authors:  R Vassilopoulou-Sellin
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

Review 7.  The relationship between oral contraceptive use, cancer and vascular disease.

Authors:  C La Vecchia; S Franceschi; P Bruzzi; F Parazzini; P Boyle
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

8.  Breast cancer screening for women younger than 40.

Authors:  A F Gili; Z Poonja; B B Kalra
Journal:  Can Fam Physician       Date:  1993-01       Impact factor: 3.275

9.  The increasing incidence of breast cancer since 1982: relevance of early detection.

Authors:  B A Miller; E J Feuer; B F Hankey
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

10.  Growth hormone mRNA in mammary gland tumors of dogs and cats.

Authors:  J A Mol; E van Garderen; P J Selman; J Wolfswinkel; A Rijinberk; G R Rutteman
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.